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Abstract
Systemic cisplatin-based chemotherapy cures >90% of patients with
metastatic germ cell tumors (GCTs). The biological basis of this exquisite
chemo-sensitivity and the resistant phenotype encountered in 10–15% of
patients with GCT is yet unclear. A defective mismatch repair pathway
leading to microsatellite instability (MSI) has been related to resistance to
cytotoxic drugs. We investigated 100 unselected GCTs and 11 clinically
defined chemotherapy-resistant GCTs for MSI using 8 mono- or dinucleo-
tide markers and the presence of the mismatch repair factors MLH1,
MSH2, and MSH6 by immunohistochemistry. The resistant tumors, both
chemo-naı¨ve (n 8) and pretreated (n 3), showed a significantly higher
incidence of MSI compared with the unselected series (45 versus 6% in at
least one locus and 36 versus 0% in >2 of 8 loci, both P < 0.001). In 5 of
all 11 unstable tumors, MSI correlated with immunohistochemical find-
ings. This study demonstrates for the first time a positive correlation
between MSI and treatment resistance in GCT.
Introduction
GCTs3 of adults are the most frequent solid tumor of Caucasian
males between 20 and 45 years of age (1). On the basis of histological,
biological, and clinical differences, GCTs are divided in seminomas
and nonseminomas (2). Even in metastatic stages, most patients with
GCTs can be cured with multiagent, CDDP-based chemotherapy (Ref.
3, for review). Despite this success, 10–15% of the patients do not
achieve a long-lasting remission with the available treatment strate-
gies and eventually die of their disease. Up to now, the biological
basis for the exquisite treatment sensitivity of most GCT has not been
elucidated. This also accounts for the mechanism of chemotherapy
resistance (Ref. 4, for review). Response to CDDP-based chemother-
apy of ovarian carcinoma has been related to MSI, i.e., alterations in
length of short repetitive sequences of the genome by small deletions
or insertions. MSI is caused by genetic or epigenetic changes in genes
of the DNA MMR pathway. Several proteins of this pathway have
been identified, including MLH1, MSH2, and MSH6 (Ref. 5, for
review), whose inactivation might result in MSI. A number of reports
deal with MSI in GCT. Although most of them showed a negative
result (6–8), one study indicated locus-specific instability (9). Thus
far, MSI has not been correlated with treatment resistance of GCT.
Here we report the results of an analysis of the presence of MSI and
the related factors MLH1, MSH2, and MSH6 in a large series of
unselected GCT and a unique series of treatment-resistant GCT.
Materials and Methods
Patients and Samples. Fresh frozen and formalin-fixed, paraffin-embed-
ded tissue from 100 unselected cases (50 seminomas and 50 nonseminomas),
in most cases together with peripheral blood, was collected between 1991 and
2001 in collaboration with urologists and pathologists in the Southwestern part
of the Netherlands. These cases were retrieved from the archive of the
Laboratory for Experimental Patho-Oncology (Department of Pathology).
Complete data on the clinical course were not available of these patients.
The resistant series consisted of 11 patients diagnosed between 1991 and
1998, treated within various trials led by Tu¨bingen University, Germany.
Patients were considered refractory, when progression or relapses of the
disease occurred despite adequate initial and salvage treatment. The tumors
were obtained either at initial diagnosis (i.e., before chemotherapy, n  8) or
by resection of a metastatic lesion in relapse (n  3).
Table 1 summarizes the characteristics of the unselected and refractory
patients. All cases were reviewed and diagnosed by an experienced pathologist
(J. W. O.) according to the WHO classification (2).
DNA Isolation and Microsatellite Analysis. Normal DNA was isolated
either from peripheral blood or, if not available, from nontumor tissue specif-
ically dissected from the tissue blocks as described before (10). DNA of
fresh-frozen tissue or paraffin-embedded tissue was isolated according to
standard procedures as described previously (4). Microsatellite analysis of
pairs of normal and tumor DNA was performed as described previously using
eight mono- or dinucleotide markers (D2S123, BAT25, BAT26, D5S346,
D17S250, BATRII, MSH6, and BAT40) with an input of 50 ng of DNA/PCR
reaction (11).
Immunohistochemistry. Paraffin sections of 3-m thickness were
mounted on APES-coated slides, deparaffinized, and rehydrated. Antigens
were unmasked by high temperature/high pressure [120°C, 1.2 bar in Na-
citrate 0.01 M (pH 6)]. MLH1, MSH2, and MSH6 were demonstrated using
mouse monoclonal antibodies (MHL1: clone G168–15, diluted 1:500; MSH2:
clone G219–1129, diluted 1:400; MSH6: clone 44, diluted 1:1000; all BD
Biosciences, Alphen aan den Rijn, the Netherlands). The sections were incu-
bated with the primary antibodies overnight at 4°C (MLH1 and MSH2) or
room temperature (MSH6). Biotin-labeled rabbit-antimouse immunoglobulins
and a biotinylated horseradish peroxidase-Streptavidin complex (both DAKO,
Glostrup, Denmark) were applied subsequently for 30 min at room temperature
each. Diamino-benzidin was used as chromogen. Normal tonsil and colon
tissue served as positive controls. Nuclear staining was scored as “strong,”
“weak,” or “absent” compared with lymphocytes as internal positive controls,
known to be positive for all markers (12).
Statistical Analysis. The two groups of unselected and refractory GCT
were compared for differences in the incidence of MSI overall and by number
of unstable loci using a two-sided Fisher’s exact test. Differences were con-
sidered significant, when the P was 0.05. Differences in time to progression
and overall survival between refractory cases with and without MSI were
analyzed by a Log-rank test.
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Results
In total, a series of 111 GCT and matched normal DNA was studied
using eight microsatellite markers. Instability was found in 6 of the
100 control GCTs (6%, three seminomas and three nonseminomas),
all of them affecting only one locus (four in BAT40, one in MSH6,
and one in D17S250). In contrast, the series of refractory GCTs
showed MSI in 5 of 11 cases (45%, all nonseminomas), 4 of which
were sampled before chemotherapy exposure. This difference was
statistically significant (P  0.001; analyzing only nonseminomas:
P  0.002). Four of these refractory tumors (three obtained before
chemotherapy and one after) showed instability in two or more loci,
which was never observed in the unselected series (P  0.001, also
for analysis of nonseminomas only). The results are summarized in
Table 2, and representative examples of the microsatellite analysis in
the refractory GCTs are shown in Fig. 1A. The refractory cases
showing MSI and those without were analyzed regarding their
progression-free survival and overall survival by the Kaplan-Meier
method and compared using the Log-rank test. The microsatellite
stable cases had a median progression-free survival time of 6 months
compared with 26 months in the group of tumors with MSI (P 0.05;
see Fig. 1B); the data for the median overall survival were 21 and 41
months, respectively (P  0.43; data not shown).
All tumors were investigated by immunohistochemistry for the
presence of the MLH1, MSH2, and MSH6 proteins. Most cases
showed an intense homogeneous nuclear staining of nearly all tumor
cells, irrespective of their histology. Three of the 100 (3%) control
tumors and 4 of the 11 refractory tumors (36%) showed a markedly
reduced signal in any of the three stainings. Examples of tumors with
a staining for MSH6 rated as “absent” and “strong” are shown in Fig.
1C, and the results are summarized in Table 2. Of note, one GCT (of
the control series) showed instability within the MSH6 locus with
concomitant loss of MSH6 protein. The immunohistochemical find-
ings in this study did only successfully predict the presence of MSI in
two of the six unstable control GCTs and in three of the five unstable
refractory GCTs. In addition, a “weak/absent” immunohistochemical
Fig. 1. A, microsatellite analysis on pairs of normal DNA/tumor DNA of seven refractory cases using D2S123 as a marker (the unstable tumors are underlined); B, Kaplan-Meier
curve for progression-free survival of patients with refractory tumors with MSI and those with microsatellite stability (MSS). The difference was borderline significant by Log-rank
test (P  0.05); C, representative examples of immunohistochemical detection of the MSH6 protein. Left panel, tumor scored “absent” (same case showed MSI in MSH6 locus); right
panel, tumor scored “strong.”
Table 2 Summary of MSI and immunohistochemical analysis on control and
refractory GCT
Unselected
(n  100)
Refractory
(n  11) Pa
MSI 6 (6%) 5 (45%) 0.001b
MSI in 1 of 8 loci 6 (6%) 1 (9%) 0.558b
MSI in 2 of 8 loci 0 4 (36%) 0.001b
IHCc negative/weak any marker 3 (3%) 4 (36%)
hMMLH1 0 4 (36%)
hMMSH2 2 (2%) 1 (9%)
hMMSH6 2 (2%) 1 (9%)
MSI correctly predicted by IHC 2 3
MSI not predicted by IHC 4 2
MSI falsely predicted by IHC 1 1
a Ps are given for differences between all tumors of the two study groups as determined
by a two-sided Fisher’s exact test.
b Analyzing only the nonseminomas of both groups, the Ps are 0.002, 0.508, and
0.001, respectively.
c IHC, immunohistochemistry.
Table 1 Baseline patient characteristicsa
Unselected
(n  100)
Refractory
(n  11)
Median age (years) 32 (14–66) 29 (18–55)
Histology
Seminoma 50 1
Nonseminoma 50 10
Mixed nonseminoma 29 7
Embryonal carcinoma 7 0
Yolk sac tumor 5 3
Mature teratoma 9 0
Time of tissue sampling
At initial diagnosis 99 8
After chemotherapy 1 3
Systemic treatment
Standard PE/PEB/PVB/PEI NA 11
Salvage high-dose chemotherapy NA 7
Median time to progression (months) NA 10 (2–149)
Median overall survival (months) NA 40 (11–180)
a P, cisplatin; E, etoposide; B, bleomycin; V, vinblastine; I, ifosfamide; NA, not
available.
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finding was found in two GCTs (one control and one refractory) in the
absence of MSI.
Discussion
The unique chemo-sensitivity of GCT is poorly understood at the
molecular level thus far. We demonstrated recently that the model
assuming a high level of wild-type P53 resulting in a low threshold for
induction of apoptosis is not correct (4). This particular study also
showed that genetic inactivation of P53 is not a major way to induce
treatment resistance in GCT as proposed previously (13).
In vitro analyses of cell lines of various origin have suggested a
correlation between MSI, MMR, and sensitivity toward CDDP, the
key substance of all combination regimens in the systemic treatment
of GCT (14, 15). A number of groups has analyzed MSI and the MMR
pathway in GCT and found a low rate of instability without correlat-
ing the results to clinical outcome (6–9). Our findings confirm these
results in a large series, including all different histological subtypes of
GCT. However, in a clinically defined group of treatment-resistant
GCT, 45% of the tumors showed MSI, most of them in two of the
eight investigated markers, a feature never encountered in any of the
control tumors. A correlation between MSI and treatment resistance
can be explained by two different mechanisms (Ref. 16, for review):
(a) the MSI renders the genome of the cancer cell prone to harbor
secondary mutations, which could be responsible for the resistant
phenotype; or (b) MMR factors could directly be involved in induc-
tion of apoptosis (17). This could result in resistance to apoptosis
independent from the presence of actual MSI. It remains to be deter-
mined to what extent these two mechanisms contribute to the resist-
ance of GCT. It is important to note that the majority of the unstable
refractory GCTs investigated in this study was sampled before expo-
sure to chemotherapy. Our data differ in this feature from in vitro data
and a study on ovarian cancer, where MSI was induced by CDDP-
based treatment (14, 18). To study the biological relevance of MSI, we
compared the progression-free and overall survival between the re-
fractory patients with and without MSI. The shorter progression-free
survival in the subgroup of refractory tumors without MSI suggests a
different clinical behavior of refractory tumors depending on the
underlying resistance mechanism. A similar observation was made in
colon cancer (19). The difference in behavior may be explained by a
higher level of resistance mediated by mechanisms other than MSI in
these tumors. The lack of a difference in overall survival might be
caused by accumulation of secondary mutations in tumors with MSI
leading to a more aggressive phenotype in the later course of the
disease. However, with the limited number of patients in the refrac-
tory group, these considerations remain speculative at this point.
Immunohistochemical demonstration of MMR factors has been
applied successfully to predict MSI in colon cancer (20). In contrast,
low protein levels of MMR factors did not correlate with MSI in cell
lines derived from gastric carcinoma (21). Our findings indicate that
assessing MLH1, MSH2, and MSH6 by immunohistochemistry is not
sensitive and specific enough to predict MSI in GCT. This difference
to the situation in colon cancer could be related to a more prominent
role of other MMR factors, like PMS1 and PMS2, in the development
of MSI in GCT, as has been suggested for prostate cancer (22).
However, the data suggest a reduced protein level of specific MMR
factors as an explanation of MSI at least in some GCT.
In summary, we demonstrate a correlation between chemotherapy
resistance and MSI in GCT. The results offer the first plausible
explanation for the clinical behavior of refractory GCT. Furthermore,
analyzing MSI shows promise to predict treatment response based on
characteristics of the primary tumor in a significant number of cases.
In this regard, the findings have to be validated prospectively.
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